Targeted therapies for cutaneous T-cell lymphomas

References

• Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005;115(4):798-812
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;5(10):3768-85
   Google Scholar
• Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007;143(7):854-9
   PubMedGoogle Scholar
• Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol 2013;149(11):1295-9
   PubMed Web of Science ®Google Scholar
• Kim Y. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome. Arch Dermatol 2003;139(7):857-66
   PubMedGoogle Scholar
• Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009;113(21):5064-73
   PubMed Web of Science ®Google Scholar
• Guitart J, Kennedy J, Ronan S, et al. Histologic criteria for the diagnosis of mycosis fungoides: proposal for a grading system to standardize pathology reporting. J Cutan Pathol 2001;28(4):174-83
   PubMed Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and sezary syndrome: a proposal of the International Society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Ca. Blood 2007;110(6):1713-22
   PubMed Web of Science ®Google Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010;28(31):4730-9
   PubMed Web of Science ®Google Scholar
• Van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis. Arch Dermatol 2002;138(2):191-8
   PubMedGoogle Scholar
• Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer 2013;49(13):2859-68
   PubMed Web of Science ®Google Scholar
• Mirvish JJ, Pomerantz RG, Falo LD, Geskin LJ. Role of infectious agents in cutaneous T-cell lymphoma: facts and controversies. Clin Dermatol 2013;31(4):423-31
   PubMedGoogle Scholar
• Sokolowska-Wojdylo M, Wenzel J, Gaffal E, et al. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome. Clin Exp Dermatol 2005;30(6):702-6
   PubMedGoogle Scholar
• Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350(19):1978-88
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010;116(5):767-71
   PubMed Web of Science ®Google Scholar
• Ortonne N, Le Gouvello S, Tabak R, et al. CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides. Exp Dermatol 2012;21(6):461-3
   PubMed Web of Science ®Google Scholar
• Poszepczynska-Guigné E, Schiavon V, D’Incan M, et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J Invest Dermatol 2004;122(3):820-3
   PubMed Web of Science ®Google Scholar
• Chong BF, Wilson AJ, Gibson HM, et al. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res 2008;14(3):646-53
   PubMedGoogle Scholar
• Krejsgaard T, Litvinov I V, Wang Y, et al. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood 2013;122(6):943-50
   PubMedGoogle Scholar
• Singer EM, Shin DB, Nattkemper LA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol 2013;133(12):2783-5
   PubMed Web of Science ®Google Scholar
• McKenzie RCT, Jones CL, Tosi I, et al. Constitutive activation of STAT3 in Sézary syndrome is independent of SHP-1. Leukemia 2012;26(2):323-31
   PubMed Web of Science ®Google Scholar
• Abraham RM, Zhang Q, Odum N, Wasik MA. The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol Ther 2011;12(12):1019-22
   PubMed Web of Science ®Google Scholar
• Verma NK, Davies AM, Long A, et al. STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. Cell Mol Biol Lett 2010;15(2):342-55
   PubMedGoogle Scholar
• Chang TP, Vancurova I. NFκB function and regulation in cutaneous T-cell lymphoma. Am J Cancer Res 2013;3(5):433-45
   PubMedGoogle Scholar
• Krejsgaard T, Vetter-Kauczok CS, Woetmann A, et al. Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006;20(10):1759-66
   PubMedGoogle Scholar
• Vaqué JP, Gómez-López G, Monsálvez V, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood 2014;123(13):2034-43
   PubMed Web of Science ®Google Scholar
• Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006;42(8):1014-30
   PubMed Web of Science ®Google Scholar
• Willemze R, Dreyling M. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v177-80
   Google Scholar
• National comprehensive cancer network. Non-Hodgkin’s lymphoma. version 2.2014 Available from: www.nccn.org/professionals/physician_gls/pdf/nhl.pdf
   Google Scholar
• Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011;118(15):4024-35
   PubMed Web of Science ®Google Scholar
• Schlaak M, Theurich S, Pickenhain J, et al. Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: a systematic review. Crit Rev Oncol Hematol 2013;85(1):21-31
   PubMed Web of Science ®Google Scholar
• Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 2008;13(2):167-74
   PubMed Web of Science ®Google Scholar
• Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/ Sézary syndrome. Blood 2003;101(11):4267-72
   PubMed Web of Science ®Google Scholar
• Querfeld C, Mehta N, Rosen ST, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma 2009;50(12):1969-76
   PubMed Web of Science ®Google Scholar
• De Masson A, Guitera P, Brice P, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol 2014;170(3):720-4
   PubMed Web of Science ®Google Scholar
• Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 2012;4:117
   Google Scholar
• Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109(11):4655-62
   PubMed Web of Science ®Google Scholar
• Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs 2012;72(9):1293-8
   PubMed Web of Science ®Google Scholar
• Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010;16(5):1520-31
   PubMed Web of Science ®Google Scholar
• Duvic M, Pinter-Brown L, Foss F, et al. Correlation of target molecule expression and overall response in refractory cutaneous T-Cell lymphoma patients dosed with mogamulizumab (KW-0761), a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4). ASH Annu Meet Abstr 2012. 120(21):3697
   Google Scholar
• Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014;32(11):1157-63
   PubMed Web of Science ®Google Scholar
• Study of KW-0761 versus vorinostat in relapsed/refractory CTCL. Available from: http://clinicaltrials.gov/show/NCT01728805
   Google Scholar
• Palanca-Wessels MC, Press OW. Advances in the treatment of hematologic malignancies using immunoconjugates. Blood 2014;2293-301
   PubMedGoogle Scholar
• Perini GF, Pro B. Brentuximab vedotin in CD30+ lymphomas. Biol Ther 2013;3:15-23
   PubMedGoogle Scholar
• Krathen M, Sundram U, Bashey S, et al. Brentuximab vedotin demonstrates significant clinical activity in relapsed or refractory mycosis fungoides with variable CD30 expression. ASH Annu Meet Abstr 2012. 120(21):797
   Google Scholar
• Duvic M, Tetzlaff M, Clos AL, et al. Phase II trial of brentuximab vedotin For CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders. Blood 2013;122(21):367
   PubMedGoogle Scholar
• A Phase 3 trial of brentuximab vedotin(SGN-35) versus physician’s choice (methotrexate or bexarotene) in patients with CD30-positive cutaneous T-cell lymphoma. Available from: http://clinicaltrials.gov/show/NCT01578499
   Google Scholar
• Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I. Immunotoxins for leukemia. Blood 2014;2470-7
   PubMedGoogle Scholar
• Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manage Res 2010;2:53-9
   PubMedGoogle Scholar
• Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19(2):376-88
   PubMed Web of Science ®Google Scholar
• Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010;28(11):1870-7
   PubMed Web of Science ®Google Scholar
• Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk 2013;13(4):377-84
   PubMed Web of Science ®Google Scholar
• A trial of E7777 in persistent and recurrent cutaneous T-cell lymphoma. Available from: http://clinicaltrials.gov/show/NCT01871727
   Google Scholar
• Frankel AE, Woo JH, Mauldin JP, et al. An update on the clinical activity of resimmune, a targeted therapy directed To CD3 receptor, in patients with cutaneous T cell lymphomas – CTCL. Blood 2013;22(21):4381
   Google Scholar
• LeMaistre CF, Rosen S, Frankel A, et al. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 1991;78(5):1173-82
   PubMed Web of Science ®Google Scholar
• Zain J, Kaminetzky D, O’Connor OA. Emerging role of epigenetic therapies in cutaneous T-cell lymphomas. Expert Rev Hematol 2010;3(2):187-203
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25(21):3109-15
   PubMed Web of Science ®Google Scholar
• Fantin VR, Loboda A, Paweletz CP, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008;68(10):3785-94
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109(1):31-9
   PubMed Web of Science ®Google Scholar
• Prince HM, Dickinson M. Romidepsin for cutaneous T-cell lymphoma. Clin Cancer Res 2012;18(13):3509-15
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre M-F, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28(29):4485-91
   PubMed Web of Science ®Google Scholar
• Kim YH, Demierre M-F, Kim EJ, et al. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leuk Lymphoma 2013;54(2):284-9
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27(32):5410-17
   PubMed Web of Science ®Google Scholar
• Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 2013;49(2):386-94
   PubMed Web of Science ®Google Scholar
• Pohlman B, Advani R, Duvic M, et al. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. ASH Annu Meet Abstr 2009. 114(22):920
   Google Scholar
• Marchi E, Mangone M, Zullo K. Pralatrexate pharmacology and clinical development. Clin Cancer Res 2013;19(24):6657-61
   PubMed Web of Science ®Google Scholar
• Wang ES, O’Connor O, She Y, et al. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003;44(6):1027-35
   PubMed Web of Science ®Google Scholar
• Malik SM, Liu K, Qiang X, et al. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2010;16(20):4921-7
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29(9):1182-9
   PubMed Web of Science ®Google Scholar
• Foss F, Horwitz SM, Coiffier B, et al. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk 2012;12(4):238-43
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012;119(18):4115-22
   PubMed Web of Science ®Google Scholar
• Koch E, Story SK, Geskin LJ. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy. Leuk Lymphoma 2013;54(11):2448-51
   PubMed Web of Science ®Google Scholar
• Talpur R, Thompson A, Gangar P, Duvic M. Pralatrexate Alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 2014. [Epub ahead of print]
   Google Scholar
• Pralatrexate and bexarotene in patients with relapsed or refractory cutaneous T-cell lymphoma. Available from: http://clinicaltrials.gov/show/NCT01134341
   Google Scholar
• Schramm VL. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents. Biochim Biophys Acta 2002;1587(2-3):107-17
   PubMed Web of Science ®Google Scholar
• Kantarjian HM. Purine nucleosidase phosphorylase (PNP): a novel target in leukemias and lymphomas. Semin Oncol 2007;34(6 Suppl 5):S1-2
   PubMedGoogle Scholar
• Duvic M, Ziari S, Olsen EA, Foss FM. Phase 1 – 2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma. Proc Am Soc Clin Oncol 2004;22:14
   Google Scholar
• Duvic M, Foss FM, Olsen EA, et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (pnp) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma. ASH Annu Meet Abstr 2004. 104(11):2491
   Google Scholar
• Duvic M, Forero-Torres A, Foss F, et al. Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. ASCO Meet Abstr 2009. 27(15S):8552
   Google Scholar
• Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36
   PubMed Web of Science ®Google Scholar
• Querfeld C, Rosen ST, Guitart J, et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood 2014;123(8):1159-66
   PubMed Web of Science ®Google Scholar
• Lenalidomide and temsirolimus in treating patients with relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma. Available from: http://clinicaltrials.gov/show/NCT01076543
   Google Scholar
• An open label, international, multi-centre, Phase I/IIa study of lenalidomide (revlimid) and romidepsin (istodax) for relapsed/refractory Hodgkin lymphoma, mature T-cell lymphoma and multiple myeloma. (RId Study) (RID). Available from: http://clinicaltrials.gov/show/NCT01742793
   Google Scholar
• National Cancer Institute. FDA Approval for bortezomib. Available from: www.cancer.gov/cancertopics/druginfo/fda-bortezomib [Last accessed 28 April 2014]
   Google Scholar
• Shen M, Schmitt S, Buac D, Dou QP. Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin Ther Targets 2013;17(9):1091-108
   PubMed Web of Science ®Google Scholar
• McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008;11(4-5):164-79
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25(27):4293-7
   PubMed Web of Science ®Google Scholar
• Herndon TM, Deisseroth A, Kaminskas E, et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013;19(17):4559-63
   PubMed Web of Science ®Google Scholar
• Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011;103(13):1007-17
   PubMedGoogle Scholar
• Dose-escalation trial of carfilzomib with and without romidepsin in cutaneous T-cell lymphoma. Available from: http://clinicaltrials.gov/show/NCT01738594
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64
   PubMed Web of Science ®Google Scholar
• Sosman JA, Haanen JB, Gonzalez R, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMedGoogle Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369(2):134-44
   PubMed Web of Science ®Google Scholar
• Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Control 2014;21(1):80-9
   PubMed Web of Science ®Google Scholar
• Eggermont A, Robert C, Soria JC, Zitvogel L. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. Oncoimmunology 2014;3(1):e27560
   Google Scholar
• O’Mahony D, Morris JC, Quinn C, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007;13(3):958-64
   PubMed Web of Science ®Google Scholar
• Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2009;15(20):6446-53
   PubMed Web of Science ®Google Scholar
• Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014;15(1):69-77
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang HY, Wei F, et al. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner. J Immunol 2014;192(6):2913-19
   PubMed Web of Science ®Google Scholar
• Wong HK, Wilson AJ, Gibson HM, et al. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides – cutaneous T cell lymphoma. J Invest Dermatol 2006;126(1):212-19
   PubMed Web of Science ®Google Scholar
• Samimi S, Benoit B, Evans K, et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol 2010;146(12):1382-8
   PubMedGoogle Scholar
• Munir S, Andersen GH, Woetmann A, et al. Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 2013;27(11):2251-3
   PubMed Web of Science ®Google Scholar
• Wu L, Parton A, Lu L, et al. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother 2011;60(1):61-73
   PubMedGoogle Scholar
• Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013;27(9):1902-9
   PubMed Web of Science ®Google Scholar
• I-SPY 2 trial: neoadjuvant and personalized adaptive novel agents to treat breast cancer. Available from: http://clinicaltrials.gov/show/NCT01042379
   Google Scholar
• S1400: lung-MAP. SWOG. Available from: www.swog.org/Visitors/newsletters/2014/04/index.asp?A=s1400 [Last accessed 5 May 2014]
   Google Scholar